Health

M&As and IPOs continue their upward trend in October, with healthcare having a standout month, characterised by big exits in the private and public markets.

The biotech producer will invest in and incubate external projects through New Ventures, as Chelsea Johnson joins from Atlas Venture to lead the unit.

After a year building ventures, Mark Yde is joining Ajinomoto Group Ventures to invest in healthcare, food and greentech.

Sanofi's venture arm is going against a pharma bear market by upping investments and hiking its fund to $1.4bn. Unit head Jason Hafler says AI opportunities are a big reason why.

Quantum is on the cusp of moving from research to commercial use and companies are exploring its potential for improving diagnostics and the discovery of new drugs.

He joins the team after stints on the investment and operational side of biotech.

Corporates frequently team up with each other to invest in startups. Who partners with who says a lot about how much a given team's track record is respected.

Third-quarter investment numbers show that investors are more trigger-happy, but not recklessly so.

The M Ventures team has seen a number of personnel changes recently, from a new managing director and CFO to principal and head of business operations.

Pharmaceutical firm Sanofi's corporate venture unit has added $625m to its evergreen fund following a succession of big exits.

Having completed his MBA and taken a couple of interim roles, Nikolas Koenning is back at The Cigna Group Ventures as principal.